These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31114280)

  • 21. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
    J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    Anwar A; Azmi KN; Hamidon BB; Khalid BA
    Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin.
    Moses RG
    Expert Rev Endocrinol Metab; 2010 May; 5(3):331-342. PubMed ID: 30861688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus.
    Younas A; Riaz J; Chughtai T; Maqsood H; Younus S; Qasim M; Saim M; Qazi S; Khaliq M; Fatima M
    Cureus; 2021 Jan; 13(1):e13045. PubMed ID: 33680590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers.
    Yamazaki M; Hasegawa G; Majima S; Mitsuhashi K; Fukuda T; Iwase H; Kadono M; Asano M; Senmaru T; Tanaka M; Fukui M; Nakamura N
    Diabetol Metab Syndr; 2014; 6():54. PubMed ID: 24843385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
    Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes.
    Richard JW; Raskin P
    Clin Med Insights Endocrinol Diabetes; 2011; 4():29-37. PubMed ID: 22879792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study.
    Gupta S; Khajuria V; Tandon VR; Mahajan A; Gillani ZH
    Perspect Clin Res; 2015; 6(3):163-8. PubMed ID: 26229753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Observational Study of Glimepiride and Metformin Fixed-Dose Combination Along With Insulin in the Management of Type 2 Diabetes Mellitus: Indian Experience.
    Prasanna Kumar KM; Seshadri K; Aravind SR; Deb P; Modi KD; Gopal RA; G VK; Moses CA; Abhyankar M; Revenkar S
    Cureus; 2021 Jan; 13(1):e13020. PubMed ID: 33665047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence.
    Sahay RK; Mittal V; Gopal GR; Kota S; Goyal G; Abhyankar M; Revenkar S
    Cureus; 2020 Sep; 12(9):e10700. PubMed ID: 33133865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes.
    Yamada H; Kakei M; Hara K
    J Clin Med Res; 2018 Nov; 10(11):838-842. PubMed ID: 30344819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update.
    Moses RG
    Diabetes Metab Syndr Obes; 2010 May; 3():145-54. PubMed ID: 21437084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.